Michael R. Clay

2.9k total citations
47 papers, 691 citations indexed

About

Michael R. Clay is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, Michael R. Clay has authored 47 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 12 papers in Rheumatology. Recurrent topics in Michael R. Clay's work include Sarcoma Diagnosis and Treatment (13 papers), Soft tissue tumor case studies (6 papers) and Cancer Genomics and Diagnostics (6 papers). Michael R. Clay is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Soft tissue tumor case studies (6 papers) and Cancer Genomics and Diagnostics (6 papers). Michael R. Clay collaborates with scholars based in United States, United Kingdom and Türkiye. Michael R. Clay's co-authors include Brent A. Orr, Sharon W. Weiss, Mark Edgar, Anthony P. Martinez, Teresa Santiago, Emília M. Pinto, Sariah J. Allen, Chimene Kesserwan, Alberto S. Pappo and V. Michael Holers and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Michael R. Clay

43 papers receiving 685 citations

Peers

Countries citing papers authored by Michael R. Clay

Since Specialization

Citations

This map shows the geographic impact of Michael R. Clay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Clay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Clay more than expected).

Fields of papers citing papers by Michael R. Clay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Clay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Clay. The network helps show where Michael R. Clay may publish in the future.

Co-authorship network of co-authors of Michael R. Clay

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Clay. A scholar is included among the top collaborators of Michael R. Clay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Clay. Michael R. Clay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Decay-Accelerating Factor Differentially Associates With Complement-Mediated Damage in Synovium After Meniscus Tear as Compared to Anterior Cruciate Ligament Injury 2024 ·Immune Network ·V. Michael Holers, Rachel M. Frank, Michael J. Zuscik, (unknown), Robert I. Scheinman, Christopher C. Striebich, Dmitri Simberg, Michael R. Clay, Larry W. Moreland, Nirmal K. Banda	2
2	Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery 2024 ·Cancer Management and Research ·Allison F. O’Neill, Raul C. Ribeiro, Emília M. Pinto, Michael R. Clay, Gerard P. Zambetti, Brent A. Orr, Christopher B. Weldon, Carlos Rodríguez‐Galindo	2
3	Comparison of DNA methylation based classification models for precision diagnostics of central nervous system tumors 2024 ·npj Precision Oncology ·Quynh T. Tran, (unknown), Tong Lin, Ruth Tatevossian, Sariah J. Allen, Michael R. Clay, Larissa V. Furtado, Jinan Chen, Dale J. Hedges, (unknown), Giles Robinson, Paul A. Northcott, Amar Gajjar, Elizabeth M. Azzato, Sheila Shurtleff, David W. Ellison, Stanley Pounds, Brent A. Orr	4
4	Dual Aldosterone- and Cortisol-Secreting Adrenal Cortical Carcinoma: Pre- and Perioperative Evaluation and Management 2023 ·JCEM Case Reports ·(unknown), Christopher D. Raeburn, Michael R. Clay, Margaret E. Wierman	1
5	Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner 2023 ·Nature Aging ·(unknown), (unknown), Lihua Liu, Chris Stubben, Brian K. Lohman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kimber Converso‐Baran, H. Atakan Ekiz, Marc Barry, Michael R. Clay, Katja Kiseljak‐Vassiliades, Thomas J. Giordano, Gary D. Hammer, (unknown)	20
6	Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway 2023 ·Cancer Research ·Michael P. Ludwig, Matthew D. Galbraith, (unknown), Amanda A. Hill, Michael R. Clay, (unknown), Breelyn A. Wilky, Anthony Elias, Joaquı́n M. Espinosa, Kelly D. Sullivan	8
7	In Situ Spatial Reconstruction of Distinct Normal and Pathological Cell Populations Within the Human Adrenal Gland 2023 ·Journal of the Endocrine Society ·Rui Fu, (unknown), Michael L. Kaufman, (unknown), (unknown), Michael R. Clay, (unknown), Katja Kiseljak‐Vassiliades, Lauren Fishbein, Neelanjan Mukherjee	2
8	TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC 2022 ·Cancers ·(unknown), Hyea Jin Gil, Emília M. Pinto, (unknown), Andrew M. Fleming, Michael R. Clay, Dongli Hu, Christopher L. Morton, Shondra M. Pruett‐Miller, Baranda S. Hansen, Xiang Chen, (unknown), Yanling Liu, Xiaotu Ma, Jun Yang, Andrew M. Davidoff, Gerard P. Zambetti, Andrew J. Murphy	3
9	Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of Subdoligranulum 2022 ·Science Translational Medicine ·(unknown), Adam R. Lefferts, Michael R. Clay, Alexander Hsu, Jennifer Seifert, Marie L. Feser, Cliff Rims, Michelle S. Bloom, Elizabeth A. Bemis, Sucai Liu, (unknown), Daniel N. Frank, M. Kristen Demoruelle, Kevin D. Deane, Eddie A. James, Jane H. Buckner, William H. Robinson, V. Michael Holers, Kristine A. Kuhn	101
10	The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma 2022 ·Developmental Cell ·Anand G. Patel, Xiang Chen, Xin Huang, Michael R. Clay, Natalia L. Komarova, Matthew J. Krasin, Alberto S. Pappo, Heather Tillman, Brent A. Orr, Justina McEvoy, Brittney Gordon, Kaley Blankenship, Colleen Reilly, Xin Zhou, Jacqueline L. Norrie, Åsa Karlström, Jiyang Yu, Dominik Wodarz, Elizabeth Stewart, Michael A. Dyer	37
11	A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor 2021 ·Neuro-Oncology Advances ·Akira Inoue, Laura J. Janke, Brian Gudenas, Hongjian Jin, Yiping Fan, Joshua Paré, Michael R. Clay, Paul A. Northcott, Angela C. Hirbe, Xinwei Cao	5
12	Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma 2021 ·The Journal of Clinical Endocrinology & Metabolism ·Michael R. Clay, Emília M. Pinto, Lauren Fishbein, Tobias Else, Katja Kiseljak‐Vassiliades	9
13	The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model 2021 ·Cancer Research ·John Jeffers, Emília M. Pinto, Jerold E. Rehg, Michael R. Clay, Jinling Wang, Geoffrey Neale, Richard J. Heath, Guillermina Lozano, Enzo Lalli, Bonald C. Figueiredo, Alberto S. Pappo, Carlos Rodríguez‐Galindo, Wenan Chen, Stanley Pounds, Raul C. Ribeiro, Gerard P. Zambetti	9
14	Methylation profiling reveals novel molecular classes of rhabdomyosarcoma 2021 ·Scientific Reports ·Michael R. Clay, Anand G. Patel, Quynh T. Tran, Dale J. Hedges, Ti‐Cheng Chang, Elizabeth Stewart, (unknown), Cynthia Cline, Michael A. Dyer, Brent A. Orr	16
15	A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies 2020 ·European Journal of Cancer ·Sara M. Federico, Alberto S. Pappo, Natasha Sahr, April Sykes, Olivia Campagne, Clinton F. Stewart, Michael R. Clay, Armita Bahrami, M. Beth McCarville, Sue C. Kaste, Victor M. Santana, (unknown), (unknown), Anang A. Shelat, Rachel C. Brennan, (unknown), (unknown), Michael W. Bishop, Wayne L. Furman, Elizabeth Stewart	44
16	MDM2 Amplification in Problematic Lipomatous Tumors 2015 ·The American Journal of Surgical Pathology ·Michael R. Clay, Anthony P. Martinez, Sharon W. Weiss, Mark Edgar	61
17	Risk of Secondary Malignancy (Including Breast) in Patients With Mismatch-repair Protein Deficiency 2014 ·The American Journal of Surgical Pathology ·Michael R. Clay, Kimberly H. Allison, Ann K. Folkins, Teri A. Longacre	1
18	MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions 2013 ·Human Pathology ·Michael R. Clay, Sushama Varma, Robert B. West	15
19	Clinicopathologic Characteristics of HER2 FISH–ambiguous Breast Cancer at a Single Institution 2012 ·The American Journal of Surgical Pathology ·Michael R. Clay, David Iberri, Charles D. Bangs, Athena M. Cherry, Kristin C. Jensen	7
20	Microscopic Uterine Lymphangioleiomyomatosis Perivascular Epithelioid Cell Neoplasm 2010 ·International Journal of Gynecological Pathology ·Michael R. Clay, Pamela Church Gibson, Jennifer L. Lowell, Kumarasen Cooper	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact